Drug Profile
Pridopidine - Prilenia Therapeutics
Alternative Names: ACR-16; ASP-2314; FR-310826; Huntexil; TV-7820Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator NeuroSearch Sweden AB
- Developer Massachusetts General Hospital; Prilenia Therapeutics; Teva Pharmaceutical Industries
- Class Antidementias; Antiparkinsonians; Antipsychotics; Eye disorder therapies; Neuropsychotherapeutics; Piperidines; Small molecules; Sulfones
- Mechanism of Action Dopamine D2 receptor antagonists; Glutamate modulators; Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Huntington's disease
- Phase II/III Amyotrophic lateral sclerosis
- Phase II Parkinson's disease
- No development reported Alzheimer's disease; Eye disorders; Fragile X syndrome; Rett syndrome
- Discontinued Schizophrenia
Most Recent Events
- 12 Mar 2024 Prilenia Therapeutics plans to submit global regulatory submissions for additional countries for Huntington’s disease
- 12 Mar 2024 Prilenia Therapeutics plans to submit a Marketing Authorization Application for the treatment of Huntington’s disease to the CHMP in mid-2024
- 19 Jan 2024 Efficacy and adverse events data from phase II/III HEALEY ALS platform trial in Amyotrophic lateral sclerosis released by Prilenia Therapeutics